Skip to main content

Table 1 Comparison between groups according to the presence of thoracic LAP on MDCT initial assessment

From: Thoracic lymphadenopathies in diffuse systemic sclerosis: an observational study on 48 patients using computed tomography

Characteristics

Total

LAP+

LAP−

p

(N = 48)

(N = 23)

(N = 25)

Epidemiological

    

Female sex (%)

30 (62.5)

9 (39.1)

21 (84)

0.002

Age in mean* ± SD (years)

52 ± 14

51 ± 10

53 ± 14

NS

Mean disease duration ± SD (years)

2.5 ± 4.1

2.3 ± 4.1

2.8 ± 4.2

NS

Silica exposure (%)

8 (16.7)

8 (34.8)

0 (0)

0.001

Tobacco exposure** (%)

14 (29.2)

8 (34.8)

6 (24)

NS

Phenotype

    

GERD (%)

47 (97.9)

22 (95.7)

25 (100)

NS

Intestinal involvement (%)

7 (14.6)

4 (17.4)

3 (12)

NS

Ano-rectal involvement (%)

5 (10.4)

1 (4.4)

4 (16)

NS

Joint involvement (fingers/hands/wrists) (%)

21 (43.7)

11 (47.8)

20 (80)

0.03

Muscular involvement (%)

4 (8.3)

1 (4.4)

3 (12)

NS

Raynaud’s phenomenon (%)

46 (95.8)

22 (95.7)

25 (100)

NS

Digital ulcer (%)

26 (54.2)

11 (47.8)

15 (60)

NS

Cutaneous calcinosis (%)

10 (20.8)

3 (13)

7 (28)

NS

Telangiectasia (%)

29 (60.4)

15 (60)

14 (56)

NS

Sicca syndrome (%)

11 (22.9)

6 (-26.1)

5 (20)

NS

Scleroderma renal crisis (%)

9 (18.8)

3 (13)

6 (24)

NS

Pericarditis (%)

5 (10.4)

1 (4.4)

4 (16)

NS

Myocardial involvement (%)

7 (14.6)

6 (26.1)

5 (20)

NS

Pulmonary hypertension (%)

5 (10.4)

3 (13)

2 (8)

NS

 Group 1 (PAH) (%)

3 (6.3)

2 (8.9)

1 (4)

NS

 Group 3 (%)

2 (4.2)

2 (8.9)

0 (0)

NS

Rodnan score*** ± SD

23 ± 8

22 ± 7.6

24 ± 8.4

NS

ILD (%)

30 (-62.5)

15 (65.2)

15 (60)

NS

Immunological

    

Anti-Scl70 antibody (%)

26 (54.2)

16 (69.6)

10 (40)

0.078

Anti-centromere antibody (%)

2 (4.2)

1 (4.4)

1 (4)

NS

Anti-RNA polymerase III antibody (%)

4 (8.3)

0 (0)

4 (16)

NS

Anti-U1RNP antibody (%)

3 (6.3)

0 (0)

3 (12)

NS

No antibody specificity (%)

15 (31.3)

6 (26.1)

9 (36)

NS

Mean CRP level in mg/L ± SD

18 ± 20

22 ± 19.8

15 ± 20.1

NS

Pulmonary function test♦♦

    

Mean FVC in mL ± SD

3024 ± 985

3185 ± 1025

2981 ± 953

NS

Mean DLCO in % ± SD

65 ± 22

61 ± 21

71 ± 21

NS

  1. LAP = lymphadenopathies; LAP +  = presence of thoracic lymphadenopathies; LAP- = absence of thoracic lymphadenopathies; GERD = gastroesophageal reflux disease; PAH = pulmonary arterial hypertension; ILD = interstitial lung disease; CRP = C-reactive protein; FVC = forced vital capacity; DLCO = diffusion capacity of carbon monoxide
  2. *Age at initial MDCT assessment; **Defined as an active consumption or a smoking cessation with estimated consumption above 10 year-pack; ***Maximal Rodnan score during follow up; CRP level at diagnosis; ♦♦Pulmonary function test at diagnosis; NS = Non statistically significant